Additional file 1 of An epithelial gene signature of trans-IL-6 signaling defines a subgroup of type 2-low asthma

Additional file 1: Table S1. Different experimental conditions of stimulation or treatment with IL-6, sIL-6Rα, Olamkicept and Tocilizumab. Table S2.Gene set enrichment analysis of the 4th quartile top 5% IL-6+sIL-6Rα induced genes (core enrichment genes). Table S3.Quantitative measurement of western-blot band density relatively compared to IL-6. Table S4. Teer Measurement after normalization, compared to control condition. Table S5. Area under the curve of real-time cell impedance measurements using xCELLigence system after 24 hours of stimulation. Table S6. Differentially expressed Genes by IL-6 vs. control.Table S7. Differentially expressed Genes by IL-6+sIL-6Rα vs. control. Table S8. Functional enrichments in genes significantly upregulated by IL-6/IL-6Rα in Biological Process (Gene Ontology). Table S9. IL-6/IL6-Rα Gene signature expression in response to Olamkicipt and Tocilizumab. Table S10. Description of the Study population. Table S11. GSEA results summary in current Asthma phenotype in bronchial biopsies cohort. Table S12. GSEA results summary in current Asthma phenotype in nasal brush cohort.